About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Waldenstrom Macroglobulinemia Treatment Options: Alkylators Are Recommended for Primary Therapy, PFS Was Significantly Higher for Ibrutinib + Rituximab vs. Rituximab (iNNOVATE Trial)
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Joshua Richter
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Joshua Richter
301 views
November 19, 2019
1 Comment
Login to view comments.
Click here to Login
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Related Content
AUTOPLAY
ON
08:18
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…
Feat.
A. Zhou
09:27
ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…
Feat.
M. McMullin
17:21
Daniel Addison
Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…
16:25
Northwestern Medicine Oncology and Hematology
Diagnosis and Goals of Therapy in PV
Feat.
B. Stein
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
10:49
Monia Marchetti
Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…
10:06
ASCO 2022 Conference Coverage
ASCO 2022 Bendamustine Rituximab vs. Ibrutinib as Primary Therapy fo…
Feat.
J. Abeykoon
08:19
ASH 2022 Conference Coverage
ASH 2022 Results From the Phase 1/2 BRUIN Study: Safety & Tolera…
Feat.
N. Shah
31:51
Indy Hematology Review
Managing Newly Diagnosed MM in 2023
Feat.
S. Usmani
03:42
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "BELLWAVE-003 - A Phase 2 Dose Escalation,…
Feat.
G. Perini
11:11
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Ibrutinib and Venetoclax in Symptomatic, Tr…
Feat.
J. Castillo
24:53
Indy Hematology Review
Emerging and Current Treatment of Amyloidosis and Waldenstrom’s Macr…
Feat.
M. Gertz
28:28
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Manage Waldenstrom’s Macroglobulinemia in the…
Feat.
S. Treon
03:40
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Long-Term Safety With ≥12 Months of Pirto…
Feat.
C. Coombs
08:34
ASH 2022 Conference Coverage
ASH 2022: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-C…
Feat.
M. Shadman
21:29
Indy Hematology Review
Indy Hematology Review 2023: Emerging Therapies in Hematologic Malig…
Feat.
R. Birhiray
25:45
Indy Hematology Review
Managing Newly Diagnosed Multiple Myeloma and Waldenstrom's Mac…
Feat.
S. Usmani
51:44
PleXus Communications
Management of Waldenstrom's Macroglobulinemia in the Era of Tar…
Feat.
S. Treon
23:36
MyCancerHaven
Experts Discuss the Basics of Diagnosis and Treatment of Waldenstrom…
Feat.
R. Vij,
J. Castillo
